From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

A free to access podcast from Tom Winnifrith for shareholders in Omega Diagnostics

By Tom Winnifrith | Friday 11 February 2022


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


I guess you are all feeling a bit shafted right now and are wondering who to blame and what to do next after today’s debacle. Contrary to what you might read on certain Bulletin Boards I do not celebrate the pain of most Omega Diagnostics (ODX) shareholders, just those who abused and insulted my 100% accurate warnings of the bailout placing and other matters. For those chumps, it is schadenfreude all round. So what should you, as an Omega shareholder, do now? I answer that question and them discuss the legality of my reporting and indeed the morality of the reporting plus I explain exactly who shareholders should be angry with on a number of matters and why. Enjoy.  My regular daily podcast, behind the paywall, will go live later today. If you are not yet a ShareProphets subscriber and do not want to get caught out again as you have been today, you can rectify that HERE


ShareProphets · A free to access podcast from Tom Winnifrith for shareholders in Omega Diagnostics
This story is available to all readers
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

Saturday »

AVCT

Cassava, A warning to Avacta Sharehoders 

Friday »

ALU

Alumasc Group – a growth Buy

 

VCP

Victoria - The roll up unravels

 

HEMO

Hemogenyx is a short – target 0p

 

ECR

ECR, the timing is unfortunate

 

APH

Alliance Pharma – a recovery Buy?

Time left: 07:19:24